TY - JOUR
T1 - Reduced adhesion of pbmncs to endothelium in methylprednisolonetreated ms patients
AU - Gelali, M.
AU - Corsim, E.
AU - Dut'Our, A.
AU - Ciusaiii, E.
AU - Massa, G.
AU - Eoli, M.
AU - Milanese, C.
AU - Nespolo, A.
AU - Salmaggi, A.
PY - 1997
Y1 - 1997
N2 - Vlethylprednisolone (MP). is a synthetic steroid commonly used in tlie treatment of Multiple Sclerosis (MS) relapses. It has a wide spectrum of activities on immune cells: it might also act by preventing mononuclear cell/endothelium adhesion. We studied adhesion phenomena between cultured human umbilical vein endothelial cells (HUVECs) and PBMNCs (CD45
+, CD14
+) from 6 MS patients treated in vivo with MP. We also studied fluctuations in CD1 la and CD18 levels on lymphocytes and monocytes, as well as changes in serum sICAM-1 andsVCAM-1 concentrations. After treatment with MP, 1000 mg in 250 ml saline ,i.v., over 1 hour, PBMNCs adhesion to endothelium decreased at 3 hours, while it went back to baseline levels at 24 hours. The fluctuations in adhesiveness were not explained by MP-induced shifts in the number of circulating monocytes and lymphocytes. A tendency to increase in both CDlla and CD 18 on the surface of lymphocytes was detected, while an increase in serum sVCAM-1 was seen at 3 hours. This increase in sVCAM-1 could partly explain the reduction in adhesion at 3 hours, as well as the findings reported by Droogan (Droogan et al. Neurology 1996) of reduced VLA-4 density on the surface of monocytes drawn from MP-treated MS patients at 6 hours, by an in vivo mechanism of VLA-4 masquerading.
AB - Vlethylprednisolone (MP). is a synthetic steroid commonly used in tlie treatment of Multiple Sclerosis (MS) relapses. It has a wide spectrum of activities on immune cells: it might also act by preventing mononuclear cell/endothelium adhesion. We studied adhesion phenomena between cultured human umbilical vein endothelial cells (HUVECs) and PBMNCs (CD45
+, CD14
+) from 6 MS patients treated in vivo with MP. We also studied fluctuations in CD1 la and CD18 levels on lymphocytes and monocytes, as well as changes in serum sICAM-1 andsVCAM-1 concentrations. After treatment with MP, 1000 mg in 250 ml saline ,i.v., over 1 hour, PBMNCs adhesion to endothelium decreased at 3 hours, while it went back to baseline levels at 24 hours. The fluctuations in adhesiveness were not explained by MP-induced shifts in the number of circulating monocytes and lymphocytes. A tendency to increase in both CDlla and CD 18 on the surface of lymphocytes was detected, while an increase in serum sVCAM-1 was seen at 3 hours. This increase in sVCAM-1 could partly explain the reduction in adhesion at 3 hours, as well as the findings reported by Droogan (Droogan et al. Neurology 1996) of reduced VLA-4 density on the surface of monocytes drawn from MP-treated MS patients at 6 hours, by an in vivo mechanism of VLA-4 masquerading.
UR - http://www.scopus.com/inward/record.url?scp=33746344050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746344050&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33746344050
VL - 18
SP - 71
JO - Italian Journal of Neurological Sciences
JF - Italian Journal of Neurological Sciences
SN - 0392-0461
IS - 4
ER -